Abstract 1728: Genetic Variations in Epidermal Growth Factor Receptor Pathway Predict Recurrence and Response to Chemotherapy in Early Stage Non-Small Cell Lung Cancer

Eric S. Kim,Yuanqing Ye,Ara A. Vaporciyan,Jinliang Xing,Maosheng Huang,Jian Gu,Jack A. Roth,Scott M. Lippman,Xifeng Wu
DOI: https://doi.org/10.1158/1538-7445.am2012-1728
IF: 11.2
2012-01-01
Cancer Research
Abstract:Abstract Purpose: We hypothesized that genetic variants within EGFR pathway would have significant predictive value for recurrence and response to chemotherapy after curative resection in early-stage NSCLC. Methods: This study included 467 patients with histologically confirmed NSCLC who were enrolled from 1995 to 2008 in an ongoing, prospective epidemiologic lung cancer study at MD Anderson Cancer Center. A total of 387 single nucleotide polymorphisms (SNPs) within 26 genes from EGFR pathway were genotyped in patients who were treated with surgery only (N=340) or surgery plus chemotherapy (N=127). The risk of recurrence was estimated as hazard ratios (HRs) and 95% confidence intervals (CIs) using a multivariate Cox proportional hazard regression model. Results: We identified 5 top SNPs that significantly (P<0.05) predicted risk of recurrence in both surgery only and surgery plus chemotherapy groups. To identify a subgroup of patients who may benefit from adjuvant chemotherapy, we divided these 5 SNPs into two different groups according to varying hazard ratios for the analysis performed in surgery only or surgery plus chemotherapy group; A (2 SNPs)=should receive surgery only (HR<1 in surgery only and HR>1 in surgery+chemotherapy); B (3 SNPs)=should receive chemotherapy in addition to surgery (HR>1 in surgery only and HR<1 in surgery+chemotherapy). Cumulative genotype analysis reveals that patients with 1 or 2 SNPs from Group A had risk of recurrence that was 0.57-fold that of the reference group without any of these two SNPs (HR=0.57; 95% CI=0.34-0.96; P=0.035). However, if patients with the same 1 or 2 SNPs undergo chemotherapy, the risk of recurrence increases to 3.3-fold that of the reference group (HR=3.28; 95% CI=1.51-7.12; P=0.003). On the other hand, patients with one or greater number of SNPs from Group B after surgery only had 2.3-fold increased risk of recurrence compared to the reference group without any of these SNPs (HR=2.30; 95% CI=1.36-3.88; P=0.002). However, with addition of chemotherapy the risk of recurrence in patients with the same SNPs decreased significantly to 0.24-fold that of the reference group (HR=0.24; 95% CI=0.12-0.51; P=0.001). Conclusions: Our proposed SNPs from EGFR pathway may help identify a subgroup of patients at high risk of recurrence after resection and guide decision for adjuvant chemotherapy in early-stage NSCLC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1728. doi:1538-7445.AM2012-1728
What problem does this paper attempt to address?